New cocktail targets Hard-to-Treat stomach cancer

NCT ID NCT07334431

Recruiting now Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a combination of three drugs (fruquintinib, trastuzumab, and chemotherapy) as a first treatment for people with HER2-positive advanced stomach or gastroesophageal junction cancer. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 45 participants will take part in this early-phase trial at one hospital in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fruquintinib, trastuzumab, oxaliplatin, capecitabine
What this could lead to: If it works, this could offer a new first-line treatment option for people with HER2-positive advanced stomach cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong: This is an early-phase, small study (45 people) at one center. The drug combo may cause significant side effects, and results may not apply to everyone. Success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST LINE THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST LINE THERAPY FRUQUINTINIB GASTRIC (STOMACH) CANCER GASTRIC ADENOCARCINOMA GEJ ADENOCARCINOMA HER2-POSITIVE GASTRIC CANCER

Contacts and locations

Locations

Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
RECRUITING

Zhengzhou, Henan, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.